X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1534) 1534
Publication (144) 144
Book Review (15) 15
Magazine Article (4) 4
Book Chapter (2) 2
Newsletter (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1257) 1257
male (866) 866
ezetimibe (767) 767
index medicus (748) 748
azetidines - administration & dosage (720) 720
female (663) 663
azetidines - therapeutic use (645) 645
middle aged (495) 495
animals (444) 444
azetidines - pharmacology (437) 437
drug therapy, combination (383) 383
aged (373) 373
pharmacology & pharmacy (370) 370
anticholesteremic agents - administration & dosage (346) 346
adult (339) 339
anticholesteremic agents - therapeutic use (332) 332
treatment outcome (305) 305
azetidines - adverse effects (297) 297
hypercholesterolemia - drug therapy (274) 274
cholesterol, ldl - blood (264) 264
cholesterol (261) 261
simvastatin (252) 252
administration, oral (234) 234
azetidines - pharmacokinetics (210) 210
dose-response relationship, drug (209) 209
cardiac & cardiovascular systems (205) 205
benzylamines (198) 198
simvastatin - administration & dosage (192) 192
rats (189) 189
hypercholesterolemia (183) 183
double-blind method (182) 182
statins (175) 175
safety (170) 170
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (164) 164
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (161) 161
medicine, general & internal (158) 158
efficacy (154) 154
mice (154) 154
atorvastatin (152) 152
anticoagulants - therapeutic use (144) 144
peripheral vascular disease (144) 144
prevention (142) 142
simvastatin - therapeutic use (139) 139
drug therapy (137) 137
anticholesteremic agents - adverse effects (135) 135
ximelagatran (131) 131
anticholesteremic agents - pharmacology (129) 129
risk factors (127) 127
abridged index medicus (126) 126
thrombin - antagonists & inhibitors (123) 123
anticoagulants - administration & dosage (119) 119
cardiovascular (118) 118
atherosclerosis (114) 114
drug combinations (113) 113
time factors (113) 113
randomized controlled trials as topic (112) 112
research (111) 111
venous thromboembolism (111) 111
double-blind (109) 109
lipids (108) 108
hypercholesterolemia - blood (107) 107
primary hypercholesterolemia (107) 107
aged, 80 and over (103) 103
rats, sprague-dawley (102) 102
atorvastatin calcium (100) 100
care and treatment (100) 100
analysis (99) 99
clinical trials as topic (98) 98
low density lipoproteins (98) 98
pharmacokinetics (97) 97
warfarin (97) 97
cholesterol - blood (95) 95
melagatran (95) 95
hematology (92) 92
therapy (92) 92
adolescent (91) 91
coronary-heart-disease (91) 91
antilipemic agents (90) 90
triglycerides - blood (88) 88
pyrroles - administration & dosage (82) 82
dosage and administration (81) 81
cholesterol absorption inhibitor (80) 80
drug administration schedule (80) 80
medicine & public health (80) 80
young adult (80) 80
heptanoic acids - administration & dosage (79) 79
sulfonamides - administration & dosage (78) 78
glycine - analogs & derivatives (77) 77
metabolism (76) 76
anticoagulants - adverse effects (75) 75
drug interactions (75) 75
risk (75) 75
cholesterol, hdl - blood (74) 74
pharmacology/toxicology (74) 74
anticoagulants (73) 73
clinical trials (73) 73
direct thrombin inhibitor (73) 73
article (72) 72
azetidines - chemistry (72) 72
cardiovascular disease (72) 72
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1444) 1444
German (35) 35
Japanese (16) 16
French (12) 12
Spanish (11) 11
Hungarian (8) 8
Italian (6) 6
Russian (5) 5
Turkish (5) 5
Czech (4) 4
Danish (3) 3
Chinese (1) 1
Dutch (1) 1
Finnish (1) 1
Korean (1) 1
Lithuanian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
JAMA, ISSN 0098-7484, 02/2005, Volume 293, Issue 6, pp. 681 - 689
CONTEXT Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple... 
ORAL XIMELAGATRAN | ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | KNEE REPLACEMENT | THERAPY | VENOUS THROMBOEMBOLISM | MELAGATRAN | INTRAVENOUS UNFRACTIONATED HEPARIN | ABSORPTION | INHIBITOR XIMELAGATRAN | SECONDARY PREVENTION | Prodrugs - administration & dosage | Recurrence | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - administration & dosage | Warfarin - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Pulmonary Embolism - complications | Double-Blind Method | Venous Thrombosis - drug therapy | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Treatment Outcome | Azetidines - administration & dosage | Azetidines - therapeutic use | Benzylamines | Aged | Prodrugs - therapeutic use | Alanine Transaminase - metabolism | Heparin, Low-Molecular-Weight - administration & dosage | Clinical trials | Cardiac arrhythmia | Thrombolytic drugs | Medical treatment | Blood clots | Low-Molecular-Weight/administration & dosage/therapeutic use | Anticoagulants/administration & dosage/therapeutic use | Pulmonary Embolism/complications | Drug Therapy | MEDICIN OCH HÄLSOVETENSKAP | Alanine Transaminase/metabolism | Warfarin/administration & dosage/therapeutic use | 80 and over | Azetidines/administration & dosage/therapeutic use | Combination | Prodrugs/administration & dosage/therapeutic use | Venous Thrombosis/complications/drug therapy/mortality | Heparin | MEDICAL AND HEALTH SCIENCES
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 6, pp. 1102 - 1109.e1
Background BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events. Objective We sought to investigate the cutaneous safety... 
Dermatology | cutaneous adverse event | rash | histology | inflammation | therapy | squamous cell carcinoma | squamous cell carcinoma therapy | ACTIVATION | IMPROVED SURVIVAL | OPEN-LABEL | DERMATOLOGY | METASTATIC MELANOMA | MEK INHIBITION | PATHWAY | RESISTANCE | RAF INHIBITORS | MUTATIONS | VEMURAFENIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Young Adult | Pyridones - administration & dosage | Carcinoma, Squamous Cell - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Azetidines - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Indoles - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma - mortality | Complications and side effects | Medical colleges | Melanoma
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1867 - 1876
Journal Article
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 08/2015, Volume 100, Issue 8, pp. 3140 - 3148
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 02/2015, Volume 74, Issue 2, pp. 333 - 340
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 08/2014, Volume 15, Issue 9, pp. 954 - 965
Journal Article
The Oncologist, ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
Journal Article
Circulation Journal, ISSN 1346-9843, 2012, Volume 76, Issue 1, pp. 176 - 183
Journal Article
Journal Article